GE HealthCare
Makes medical imaging systems, diagnostic agents, patient monitors, and related software and services.
Something off on this page? Send us feedback.
Profile
Sells medical imaging, ultrasound and image-guided systems, contrast media and radiopharmaceuticals, and patient-monitoring and life-support equipment. Revenue combines capital equipment with service contracts, software and recurring consumables across a global hospital customer base.
Organized around Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions, supplies CT, MR, molecular imaging and X-ray systems; specialized ultrasound and image-guided technologies; contrast media and radiopharmaceuticals; and patient-monitoring, diagnostic-cardiology, maternal-infant and anesthesia equipment. AI-enabled software, cloud tools and enterprise imaging connect parts of these clinical workflows.
Sells globally to hospitals, health systems and researchers through direct teams and distributors. Its commercial model pairs equipment with long-term maintenance, lifecycle upgrades, software subscriptions and repeat-use diagnostic agents. Demand depends on provider capital budgets and reimbursement; products face market-specific authorization, quality and supply-chain requirements.
Company facts
Key statistics
Year to date −13.4% · Average volume (30d) 4.0M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 30, 2026 | Evercore ISI | Reiterate | Outperform | $80 | $84 | |
| Jul 29, 2026 | BTIG | Reiterate | Buy | $75 | $79 | |
| Jul 16, 2026 | UBS | Reiterate | Neutral | $69 | $67 | |
| Jul 13, 2026 | BTIG | Reiterate | Buy | $91 | $75 | |
| Jul 8, 2026 | BMO Capital | Initiate | Market Perform | $70 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 29, 2026Q2 FY26 | $1.04 | $1.13 | +8.7% | $5.26B | $5.30B | +0.6% | +12.15% |
| Apr 29, 2026Q1 FY26 | $1.04 | $0.99 | −4.8% | $5.04B | $5.13B | +1.8% | +2.27% |
| Feb 4, 2026Q4 FY25 | $1.40 | $1.44 | +2.9% | $5.61B | $5.70B | +1.5% | −0.39% |
| Oct 29, 2025Q3 FY25 | $1.05 | $1.07 | +1.9% | $5.09B | $5.14B | +1.1% | −3.08% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $4.78B | $5.01B | $5.14B | $4.67B | $5.13B | $5.30B | |
| Gross profit | $2.01B | $1.99B | $1.99B | $2.54B | $1.98B | $2.18B | |
| Operating income | $629.0M | $654.0M | $653.0M | $664.0M | $515.0M | $739.0M | |
| Net income | $564.0M | $486.0M | $446.0M | $184.0M | $389.0M | $573.0M | |
| Diluted EPS | $1.23 | $1.06 | $0.98 | $0.38 | $0.85 | $1.24 | |
| Gross margin | 42.1% | 39.7% | 38.7% | 54.3% | 38.5% | 41.2% | |
| Operating margin | 13.2% | 13.1% | 12.7% | 14.2% | 10.0% | 14.0% |
Fiscal years (4-quarter sums)FY21 $17.59B · FY22 $18.34B · FY23 $19.55B · FY24 $19.67B · FY25 $19.60B
Revenue by product · Q2 FY26
Revenue by geography · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $2.11B · Total debt $10.09B · Total assets $37.25B · Shareholders' equity $10.98B
Dividends
Last raised to $0.035 from $0.03 in Jan 2025. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jul 24, 2026 | Jul 24 | Aug 14 | $0.035 | |
| Apr 2, 2026 | Apr 3 | May 15 | $0.035 | |
| Jan 9, 2026 | Jan 9 | Feb 13 | $0.035 | |
| Oct 24, 2025 | Oct 24 | Nov 14 | $0.035 | |
| Jul 25, 2025 | Jul 25 | Aug 15 | $0.035 | |
| Apr 25, 2025 | Apr 25 | May 15 | $0.035 | |
| Jan 14, 2025 | Jan 14 | Feb 14 | $0.035 | raised from $0.03 |
| Oct 18, 2024 | Oct 18 | Nov 15 | $0.03 |
Ownership
Shares outstanding 451.69M · Float 450.34M · 99.7% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Dodge & Cox | 37.86M | 8.38% | 13F | Aug 13, 2026 |
| BlackRock, Inc. | 37.47M | 8.30% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 29.72M | 6.58% | 13F | Aug 13, 2026 |
| State Street Corp | 20.86M | 4.62% | 13F | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 20.28M | 4.49% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 22, 2026 | Kevin Lobo | director | +10,000 | $64.18 |
| May 12, 2026 | Rodney F. Hochman | director | +1,618 | $62.03 |
| May 8, 2026 | Watkin Phoebe L. Yang | director | +1,000 | $63.01 |
| May 6, 2026 | William J. Stromberg | director | +1,000 | $61.69 |
| May 6, 2026 | H. Lawrence Jr Culp | director | +80,805 | $61.88 |
Peers
- Philips (ADR)
Competes across imaging, cardiovascular ultrasound, and patient monitoring.
- Lantheus
Radiopharmaceutical pure-play; PYLARIFY PSMA PET overlaps with GEHC Flyrcado.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| GE HealthCare | $71.73 | −0.01% | $32.40B | 20.8 | 13.8 | 1.6 | +5.8% |
| Philips (ADR) | $26.72 | +0.06% | $26.12B | 19.9 | 13.7 | 1.3 | −2.9% |
| Lantheus | $100.51 | −0.24% | $6.56B | 24.3 | 18.3 | 4.2 | +2.7% |
| Median | 22.1 | 16.0 | 2.7 | −0.1% |